Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion.

Wang W, Yang X, Dai J, Lu Y, Zhang J, Keller ET.

Oncogene. 2019 Feb 12. doi: 10.1038/s41388-019-0736-3. [Epub ahead of print]

PMID:
30755731
2.

Growth differentiation factor-15 upregulates interleukin-6 to promote tumorigenesis of prostate carcinoma PC-3 cells.

Tsui KH, Chang YL, Feng TH, Chung LC, Lee TY, Chang PL, Juang HH.

J Mol Endocrinol. 2012 Sep 5;49(2):153-63. doi: 10.1530/JME-11-0149. Print 2012 Oct.

PMID:
22872134
3.

MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2.

Colden M, Dar AA, Saini S, Dahiya PV, Shahryari V, Yamamura S, Tanaka Y, Stein G, Dahiya R, Majid S.

Cell Death Dis. 2017 Jan 26;8(1):e2572. doi: 10.1038/cddis.2017.15.

4.

Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion.

Griner SE, Joshi JP, Nahta R.

Biochem Pharmacol. 2013 Jan 1;85(1):46-58. doi: 10.1016/j.bcp.2012.10.007. Epub 2012 Oct 17.

5.

The role of GDF15 in bone metastasis of lung adenocarcinoma cells.

Duan L, Pang HL, Chen WJ, Shen WW, Cao PP, Wang SM, Liu LL, Zhang HL.

Oncol Rep. 2019 Apr;41(4):2379-2388. doi: 10.3892/or.2019.7024. Epub 2019 Feb 21.

PMID:
30816507
6.

Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer.

Zhuo YJ, Liu ZZ, Wan S, Cai ZD, Xie JJ, Cai ZD, Song SD, Wan YP, Hua W, Zhong W, Wu CL.

Biomed Pharmacother. 2018 Jun;102:531-538. doi: 10.1016/j.biopha.2018.03.079. Epub 2018 Mar 26.

PMID:
29587239
7.

Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.

Meier JC, Haendler B, Seidel H, Groth P, Adams R, Ziegelbauer K, Kreft B, Beckmann G, Sommer A, Kopitz C.

Cancer Med. 2015 Feb;4(2):253-67. doi: 10.1002/cam4.354. Epub 2014 Dec 10.

8.

Macrophage inhibitory cytokine-1 (MIC-1/GDF15) slows cancer development but increases metastases in TRAMP prostate cancer prone mice.

Husaini Y, Qiu MR, Lockwood GP, Luo XW, Shang P, Kuffner T, Tsai VW, Jiang L, Russell PJ, Brown DA, Breit SN.

PLoS One. 2012;7(8):e43833. doi: 10.1371/journal.pone.0043833. Epub 2012 Aug 27.

9.

LRP5 knockdown: effect on prostate cancer invasion growth and skeletal metastasis in vitro and in vivo.

Rabbani SA, Arakelian A, Farookhi R.

Cancer Med. 2013 Oct;2(5):625-35. doi: 10.1002/cam4.111. Epub 2013 Sep 5.

10.

Macrophage inhibitory cytokine-1 (MIC-1/GDF15) gene deletion promotes cancer growth in TRAMP prostate cancer prone mice.

Husaini Y, Lockwood GP, Nguyen TV, Tsai VW, Mohammad MG, Russell PJ, Brown DA, Breit SN.

PLoS One. 2015 Feb 19;10(2):e0115189. doi: 10.1371/journal.pone.0115189. eCollection 2015.

11.

Twist promotes invasion and cisplatin resistance in pancreatic cancer cells through growth differentiation factor 15.

Ji H, Lu HW, Li YM, Lu L, Wang JL, Zhang YF, Shang H.

Mol Med Rep. 2015 Sep;12(3):3841-3848. doi: 10.3892/mmr.2015.3867. Epub 2015 May 27.

PMID:
26018318
12.

Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.

Ding G, Fang J, Tong S, Qu L, Jiang H, Ding Q, Liu J.

Prostate. 2015 Jun 15;75(9):957-68. doi: 10.1002/pros.22978. Epub 2015 Feb 25.

PMID:
25728945
13.

Growth differentiation factor 15 induces growth and metastasis of human liver cancer stem-like cells via AKT/GSK-3β/β-catenin signaling.

Xu Q, Xu HX, Li JP, Wang S, Fu Z, Jia J, Wang L, Zhu ZF, Lu R, Yao Z.

Oncotarget. 2017 Mar 7;8(10):16972-16987. doi: 10.18632/oncotarget.15216.

14.

The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL.

Emmerson PJ, Wang F, Du Y, Liu Q, Pickard RT, Gonciarz MD, Coskun T, Hamang MJ, Sindelar DK, Ballman KK, Foltz LA, Muppidi A, Alsina-Fernandez J, Barnard GC, Tang JX, Liu X, Mao X, Siegel R, Sloan JH, Mitchell PJ, Zhang BB, Gimeno RE, Shan B, Wu X.

Nat Med. 2017 Oct;23(10):1215-1219. doi: 10.1038/nm.4393. Epub 2017 Aug 28.

PMID:
28846098
15.

GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma.

Yang CZ, Ma J, Zhu DW, Liu Y, Montgomery B, Wang LZ, Li J, Zhang ZY, Zhang CP, Zhong LP.

Ann Oncol. 2014 Jun;25(6):1215-22. doi: 10.1093/annonc/mdu120. Epub 2014 Mar 24.

PMID:
24669014
16.

CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.

Gravina GL, Mancini A, Muzi P, Ventura L, Biordi L, Ricevuto E, Pompili S, Mattei C, Di Cesare E, Jannini EA, Festuccia C.

Prostate. 2015 Sep;75(12):1227-46. doi: 10.1002/pros.23007. Epub 2015 Jun 12.

PMID:
26073897
17.

NEDD9 crucially regulates TGF-β-triggered epithelial-mesenchymal transition and cell invasion in prostate cancer cells: involvement in cancer progressiveness.

Morimoto K, Tanaka T, Nitta Y, Ohnishi K, Kawashima H, Nakatani T.

Prostate. 2014 Jun;74(8):901-10. doi: 10.1002/pros.22809. Epub 2014 Apr 12.

PMID:
24728978
18.

Solid stress-induced migration is mediated by GDF15 through Akt pathway activation in pancreatic cancer cells.

Kalli M, Minia A, Pliaka V, Fotis C, Alexopoulos LG, Stylianopoulos T.

Sci Rep. 2019 Jan 30;9(1):978. doi: 10.1038/s41598-018-37425-6.

19.

Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.

Li X, Liu Y, Wu B, Dong Z, Wang Y, Lu J, Shi P, Bai W, Wang Z.

Oncol Rep. 2014 Dec;32(6):2605-11. doi: 10.3892/or.2014.3511. Epub 2014 Sep 23.

PMID:
25333856
20.

TR4 nuclear receptor promotes prostate cancer metastasis via upregulation of CCL2/CCR2 signaling.

Ding X, Yang DR, Lee SO, Chen YL, Xia L, Lin SJ, Yu S, Niu YJ, Li G, Chang C.

Int J Cancer. 2015 Feb 15;136(4):955-64. doi: 10.1002/ijc.29049. Epub 2014 Jul 14.

Supplemental Content

Support Center